From GlobeNewswire: 2025-06-01 19:30:00

Nxera Pharma Co., Ltd. announces the achievement of a development milestone in collaboration with Eli Lilly and Company targeting diabetes and metabolic diseases. The undisclosed payment from Lilly represents significant progress in research and development. Nxera is set to receive the milestone payment in the third quarter of 2025. The collaboration utilizes Nxera’s NxWave™ platform for drug design, with Lilly taking over further development and commercialization. Nxera stands to receive up to US$694 million in development and commercial milestones, along with royalties on global sales. This milestone marks a crucial step in developing treatments for unmet needs in diabetes and metabolic diseases.



Read more at GlobeNewswire: Nxera Pharma Achieves Development Milestone in